Landos Biopharma plans to raise $100 million in its initial public offering by offering 6.3 million shares at a price range of $15 to $17, as reported by NASDAQ.
Landos leverages its proprietary artificial intelligence (AI)-based precision medicine LANCE platform to identify novel therapeutic targets based on predictions of immunometabolic function.
The company’s lead candidate, BT-11, has completed the induction phase of a Phase II trial in mild to moderate ulcerative colitis patients in the US, Russia, and Europe.
It expects to initiate a Phase III trial of BT-11 for ulcerative colitis and a Phase II trial of BT-11 for moderate to severe Crohn's disease in the first half of 2021.
To read more NewsPoints articles, click here.